Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy
Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.
1. A pharmaceutical composition for treating a hepatitis B virus infection in a human patient, comprising from about 0.1 mg to about 100 mg of N-(n-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol and from about 0.1 mg to about 500 mg of (−)-2′-deoxy-3′-thiocytidine-5′-triphosphate.
2. A pharmaceutical composition for treating hepatitis virus infection, comprising a first amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:
wherein R is selected from the group consisting of straight chain alkyl having a chain length of C 7 to C 12 and
W, X, Y, and Z are each independently selected from the group consisting of hydrogen, and butanoyl; and
a second amount of an antiviral compound selected from the group consisting of 2′,3′-dideoxycytidine, 2′,3′-dideoxycytidine-5′-triphosphate, (−)-2′,3′-dideoxy-3′-thiacytidine, (−)-2′-deoxy-3′-thiocytidine-5′-triphosphate, and mixtures thereof and a pharmaceutical acceptable carrier, diluent, or excipient
wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.
3. The pharmaceutical composition of claim 2 , wherein R is a straight chain alkyl having a chain length of C 7 to C 12 and W, X, Y, and Z are each hydrogen.
4. The pharmaceutical composition of claim 3 , wherein R is nonyl.
5. The pharmaceutical composition of claim 2 , wherein R is nonyl and W, X, Y, and Z are each butanoyl.
6. The pharmaceutical composition of claim 2 , wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate, and said antiviral compound is (−)-2′-deoxy-3′-thiocytidine-5′-triphosphate.
7. The pharmaceutical composition of claim 6 , wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol.
8. The pharmaceutical composition of claim 2 , wherein said first amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 0.1 mg to about 100 mg.
9. The pharmaceutical composition of claim 2 , wherein said second amount of said nucleoside or nucleotide antiviral compound, or mixture thereof, is in the range of from about 0.1 mg to about 500 mg.